ArticleMolecules (Basel, Switzerland)2019
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 88 citations in OpenAlex.
- Andrographolide augments methotrexate's therapeutic potential in psoriasis: comprehensive in vitro and in vivo evaluation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ginsenoside Rg3 Ameliorates Psoriasis-Like Dermatitis through Inhibition of NF-κB/NLRP3 Inflammasome Signaling and Regulating Th17/Treg Balance.Immunity, inflammation and disease · 2026Article
- GPR108 Negatively Regulates TLR7 Signaling in Imiquimod-Induced Psoriasiform Dermatitis.Immunity, inflammation and disease · 2026Article
- Machine learning meets psoriasis: identifying key lactylation biomarkers as potential targets for diagnosis and therapies.Frontiers in immunology · 2026Article
- The multifaceted role of NF-κB signaling in psoriasis: from inflammatory amplification to epidermal remodeling.Frontiers in immunology · 2026Review
- Genus Datura: An Exploration of Genetic Alterations, Bioactive Compounds, and Pharmacological Activity.Plants (Basel, Switzerland) · 2025Review
- Genetic deletion of microsomal prostaglandin E synthase-1 promotes imiquimod-induced psoriasis in mice.Inflammation and regeneration · 2025Article
- TLR2 promotes the progression of diabetes mellitus with atherosclerosis via activating NLRP3 inflammasome and MyD88/NF-κB signaling pathway.Scientific reports · 2025Article
- Quantitative Proteomic Analysis Indicates That Pggt1b Deficiency Promotes Cytokine Secretion in Resiquimod-Stimulated Bone Marrow-Derived Macrophages via the NF-κB Pathway.Immunity, inflammation and disease · 2025Article
- Elucidating the molecular association and potential mechanisms between psoriasis and atrial fibrillation through biomarker and immune infiltration analysis.Archives of dermatological research · 2025Article
- Structure modification of luteolin and the influence of its derivatives on biological activities.Frontiers in nutrition · 2025Article
- Tanshinone I Ameliorates Psoriasis-Like Dermatitis by Suppressing Inflammation and Regulating Keratinocyte Differentiation.Drug design, development and therapy · 2025Article
- Article
- PANoptosis signaling enables broad immune response in psoriasis: From pathogenesis to new therapeutic strategies.Computational and structural biotechnology journal · 2024Article
- Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis.ACS pharmacology & translational science · 2024Article
- Silicone dressing combined with topical oxygen therapy alleviates incontinence-associated dermatitis via NF-κB p65/STAT1 signaling pathway.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Immune Stimulation with Imiquimod to Best Face SARS-CoV-2 Infection and Prevent Long COVID.International journal of molecular sciences · 2024Review
- miR-548ag promotes DPP4 expression in hepatocytes through activation of TLR(7/8)/NF-κB pathway.International journal of obesity (2005) · 2024Article
- Nanophytosomal Gel ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Dermal Delivery ofRecent advances in drug delivery and formulation · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPsoriasis is a chronic, immune-mediated inflammatory skin disease, and the inflammatory response plays an important role in its development and progression.
methodsAn imiquimod-induced psoriasis-like dermatitis mouse model was constructed to evaluate the protective effect of the effective part of
resultsEPD significantly decreased the PASI, reduced epidermal thickness, and decreased the proliferation and differentiation of epidermal cells in psoriasis-like dermatitis C57BL/6 mice induced by imiquimod (IMQ). Furthermore, EPD reduced the infiltration of CD3+ cells to psoriatic lesions, as well as ameliorated the elevations of intercellular adhesion molecule 1 (ICAM-1) and inhibited the production of imiquimod-induced inflammatory cytokines, including IL-1β, IL-2, IL-6, IL-10, IL-12, IL-17, IL-22, IL-23, tumor necrosis factor-α (TNF-α), monocyte chemotactic protein 1 (MCP-1), and interferon-γ (IFN-γ). Besides, EPD decreased the imiquimod-induced expression levels of TLR7, TLR8, TRAF6, MyD88, p-IKKα, p-IKBα, p-NF-κB, NLRP3, apoptosis-associated speck-like protein contained a caspase recruitment domain (ASC), cysteinyl aspartate specific proteinase 1 (caspase-1), and IL-1β.
conclusionThis study demonstrated that EPD exhibited a protective effect on an imiquimod-induced psoriasis mice model by inhibiting the inflammatory response, which might be ascribed to the inhibition of the TLR7/8-MyD88-NF-κb-NLRP3 inflammasome pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.